硝酸镓用于晚期恶性黑色素瘤患者的II期试验。
Phase II trial of gallium nitrate in patients with advanced malignant melanoma.
作者信息
Casper E S, Stanton G F, Sordillo P P, Parente R, Michaelson R A, Vinceguerra V
出版信息
Cancer Treat Rep. 1985 Sep;69(9):1019-20.
PMID:4028034
Abstract
A phase II trial of gallium nitrate (250-300 mg/m2/day for 7 consecutive days) was conducted in patients with metastatic melanoma. Therapy was well-tolerated, but only one of 31 evaluable patients experienced a partial regression. Further evaluation of gallium nitrate at this dose and schedule is not warranted in patients with malignant melanoma.
摘要
对转移性黑色素瘤患者进行了硝酸镓的II期试验（连续7天，剂量为250 - 300 mg/m²/天）。治疗耐受性良好，但31例可评估患者中只有1例出现部分缓解。对于恶性黑色素瘤患者，不建议按此剂量和疗程进一步评估硝酸镓。
Zotero 插件